At a glance
- Originator MGI GP
- Class Antidementias; Antiparkinsonians; Neuroprotectants; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 17 Apr 2007 Discontinued - Preclinical for Parkinson's disease in USA (PO)
- 28 Oct 2005 Guilford Pharmaceuticals is now called MGI GP Inc
- 05 Oct 2005 Guilford Pharmaceuticals has been acquired by MGI Pharma